14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)

Li, W.; Yang, N.; Li, K.; Fan, H.; Yu, Q.; Wu, H.; Wang, Y.; Meng, X.; Wu, J.; Wang, Z.; Liu, Y.; Wang, X.; Qin, X.; Lu, K.; Zhuang, W.; He, S.; Janne, P.A.; Seto, T.; Ou, S-H.I.; Zhou, C.

doi:10.1016/s1556-0864(23)00268-x

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the TRUST-1 trial were recently shown; this trial involved two stages: stage 1 involved just six patients and stage 2 had two groups of patients, one TKI-naïve and another one previously treated with crizotinib. In patients who were TKI-naïve, taletrectinib induced an ORR of 92.5%, with a disease control rate of 95.5%, and with a median duration of response and PFS that were not reached; in the group of patients who were pretreated with crizotinib, taletrectinib induced an ORR of 52.6%, with a median duration of response that was not reached, with a disease control rate of 81.6% and the median PFS of 9.8 months [39,40]. The overall response rate in patients with intracranial disease was 90%.…”

Section: Taletrectinibmentioning

confidence: 99%

“…The overall response rate in patients with intracranial disease was 90%. Importantly, taletrectinib induced responses in 80% of patients whose tumors harbored the G2032R resistance mutation [39,40] (Table 2). -----------------29 [39,40] Based on the clinical data accumulated to date, taletrectinib has been granted breakthrough therapy designation by the FDA for the treatment of adult patients with advanced or metastatic ROS1-positive NSCLC who are either TKI-treatment naïve or were previously pretreated with crizotinib.…”

Section: Taletrectinibmentioning

confidence: 99%

See 1 more Smart Citation

ROS1-Rearranged Lung Adenocarcinoma: From Molecular Genetics to Target Therapy

Testa,

Castelli,

Pelosi

2023

Onco

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is a heterogeneous group of diseases accounting for 80–85% of lung cancers. A molecular subset of NSCLC (1–2.5%) harboring molecular rearrangements of the tyrosine kinase gene ROS1 is defined as ROS1-positive and is almost exclusively diagnosed in patients with lung adenocarcinoma histology, predominantly nonsmokers. ROS1 is constitutively activated by molecular rearrangements and acts as a main driver of lung carcinogenesis. These findings have provided a strong rationale for the clinical use of tyrosine kinase inhibitors that target ROS1; these inhibitors block ROS1-positive NSCLC and provide clinical benefit. Crizotinib was introduced as a first-line treatment for ROS1-positive NSCLCs, with 75–80% of patients responding and a PFS of about 20 months. More recently developed ROS1-TKIs, such as entrectinib, lorlatinib, taletrectinib, repotrectinib and NVL-520, are active against some resistant ROS1 mutants appearing during crizotinib therapy and more active against brain metastases, frequent in ROS1-positive NSCLC. The development of resistance mechanisms represents a great limitation for the targeted treatment of ROS1-positive NSCLCs with TKIs.

show abstract

Section: Taletrectinibmentioning

confidence: 99%